Compare PLSE & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | PGEN |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2015 | 2013 |
| Metric | PLSE | PGEN |
|---|---|---|
| Price | $28.58 | $5.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $22.00 | $8.33 |
| AVG Volume (30 Days) | 329.0K | ★ 5.1M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $840.00 | $1,115.92 |
| Revenue Next Year | $287.54 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $1.47 |
| 52 Week High | $31.00 | $6.04 |
| Indicator | PLSE | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 49.08 |
| Support Level | $23.94 | $3.96 |
| Resistance Level | $31.00 | $5.47 |
| Average True Range (ATR) | 1.58 | 0.29 |
| MACD | -0.05 | -0.11 |
| Stochastic Oscillator | 70.14 | 19.83 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.